Cryo-Cell Signs License Agreement With S-Evans Biosciences

Cryo-Cell has signed an exclusive license agreement with S-Evans Biosciences, (SEB). The partnership will allow SEB to market and manufacture proprietary C’elle menstrual stem cell technology including the processing and storage of menstrual stem cells (MenSCs) exclusively throughout mainland China.

The agreement will also allow SEB to conduct scientific research studies using Cryo-Cell’s proprietary C’elle menstrual stem technology to identify future potential therapeutic applications for a broad possible range of diseases that may affect millions of people.

The exclusive license agreement with SEB will provide Cryo-Cell with future royalty fees from the processing and annual storage of menstrual stem cells.

Charlie Xiang, CEO of SEB, said: Stem cell research and development is well-recognized and fast-emerging in China. SEB believes that the proprietary technology of C’elle may provide women with the novel opportunity to collect and cryopreserve their own stem cells that have demonstrated considerable potential to be used in future therapies and are easily harvest from a non-controversial source.

Through SEB’s expansive educational, scientific and medical affiliations, we anticipate that there may possibly be enormous potential opportunity to successfully market the compelling and highly differentiated quality service of C’elle. We are also eager to explore prospective opportunities with Cryo-Cell to collaborate on research and development of future potential stem cell therapies that may utilize this breakthrough technology.